Neumora Therapeutics annual return on equity
2023
2024
2025
Neumora Therapeutics Return on Equity (ROE) Growth & History (NMRA)
Neumora Therapeutics's return on equity was −121.21% for fiscal 2025.
View full Neumora Therapeutics company overviewNeumora Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −121.21% | −56.73 pp |
| 2024 | 2024-12-31 | −64.48% | +2058.48 pp |
| 2023 | 2023-12-31 | −2,122.96% | — |
Neumora Therapeutics quarterly return on equity
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −74.80% | −49.15 pp |
| Q1 2026 | 2026-03-31 | −61.25% | −34.87 pp |
| Q4 2025 | 2025-12-31 | −50.37% | −31.02 pp |
| Q3 2025 | 2025-09-30 | −36.03% | −15.36 pp |
| Q2 2025 | 2025-06-30 | −25.64% | −11.08 pp |
| Q1 2025 | 2025-03-31 | −26.38% | −14.36 pp |
| Q4 2024 | 2024-12-31 | −19.35% | +2.80 pp |
| Q3 2024 | 2024-09-30 | −20.67% | +140.40 pp |
| Q2 2024 | 2024-06-30 | −14.57% | — |
| Q1 2024 | 2024-03-31 | −12.02% | — |
| Q4 2023 | 2023-12-31 | −22.15% | — |
| Q3 2023 | 2023-09-30 | −161.07% | — |
Neumora Therapeutics return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Neumora Therapeutics's return on equity increased from −2,122.96% to −121.21%, a change of +2001.75 percentage points. The latest reported quarter, Q2 2026, shows −74.80%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neumora Therapeutics source filings ↗